BULLFROG AI HOLDINGS, INC. Cost of Revenue
BULLFROG AI HOLDINGS, INC. (BFRG) reported Cost of Revenue of $108.49 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-08-14
- BULLFROG AI HOLDINGS, INC. cost of revenue for the quarter ending 2026-06-30 was $108.49K, a 305.78% increase year-over-year.
- BULLFROG AI HOLDINGS, INC. cost of revenue for the quarter ending 2025-12-31 was $0.00.
- BULLFROG AI HOLDINGS, INC. cost of revenue for the quarter ending 2025-09-30 was $68.04K.
- BULLFROG AI HOLDINGS, INC. cost of revenue for the quarter ending 2025-06-30 was $26.73K.
- BULLFROG AI HOLDINGS, INC. cost of revenue for fiscal 2025 was $94.78K.
- BULLFROG AI HOLDINGS, INC. cost of revenue for fiscal 2023 was $5.20K, a 550.00% increase from fiscal 2022.
- BULLFROG AI HOLDINGS, INC. cost of revenue for fiscal 2022 was $800.00.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $108.49K 10-Q · filed 2026-08-14 | $108.49K 10-Q · filed 2026-08-14 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $68.04K derived: sum of 2 quarters · filed 2026-03-19 | $94.78K derived: sum of 3 quarters · filed 2026-08-14 | $94.78K 10-K · filed 2026-03-19 |
| 2025-09-30 | $68.04K 10-Q · filed 2025-11-14 | $94.78K derived: sum of 2 quarters · filed 2026-08-14 | $94.78K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $26.73K 10-Q · filed 2026-08-14 | $26.73K 10-Q · filed 2026-08-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $5.20K derived: sum of 2 quarters · filed 2025-03-14 | $5.20K 10-K · filed 2025-03-14 | |
| 2023-09-30 | $5.20K 10-Q · filed 2024-11-08 | $5.20K 10-Q · filed 2024-11-08 | ||
| 2022-12-31 | $800.00 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B |